SOPHiA GENETICS S.A. Q4 2025 Earnings Call Summary

Core Insights - The company achieved a 22% total revenue growth in Q4 2025, primarily driven by a 31% increase in clinical revenue as the core business re-accelerated toward historical levels [1] - The company processed nearly 1 petabyte of genomic data in 2025, doubling the volume from two years ago due to a market shift toward large comprehensive panels and multi-omic analysis [1] - The adjusted gross margin expanded by 140 basis points to 74.2% through a major architectural modernization that increased compute capacity tenfold and reduced whole genome analysis time to under 6 hours [1] Business Development - The company secured two of the largest integrated health systems in the US, representing a combined potential of 60,000 annual genomic tests and 1 million oncology/rare disease patients [1] - The company maintained high platform stickiness with an annualized revenue churn below 1% and a Net Promoter Score of 67, validating the decentralized AI deployment model [1] Leadership Transition - A leadership transition was announced with Ross Muken set to become CEO in July 2026, while founder Jurgi Camblong will move to Executive Chairman to focus on technical innovation [1] Innovation and Technology - The company leveraged a diverse data stream from 75 countries to launch 'Digital Twins' for lung cancer, enabling AI-driven virtual simulations for therapy selection [1]